Clathrin-dependent APP endocytosis and Aβ secretion are highly sensitive to the level of plasma membrane cholesterol

Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

Volumn 1801, Issue 8, 2010, Pages 846-852

  Cossec, Jack Christophe ^a   Simon, Anne ^b   Marquer, Catherine ^a   Moldrich, Randal X ^b   Leterrier, Christophe ^b   Rossier, Jean ^b   Duyckaerts, Charles ^a   Lenkei, Zsolt ^b   Potier, Marie Claude ^a  

^a INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE   (France)

^b Brain Plasticity Unit   (France)

Author keywords

Alzheimer's disease; Amyloid ; Cholesterol; Clathrin; Endocytosis

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; CANNABINOID 1 RECEPTOR; CLATHRIN; DYNAMIN II; EPIDERMAL GROWTH FACTOR RECEPTOR PATHWAY SUBSTRATE 15; METHYL BETA CYCLODEXTRIN; RAB PROTEIN; TRANSFERRIN RECEPTOR;

AMINO TERMINAL SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL MEMBRANE; CELLULAR DISTRIBUTION; CHOLESTEROL BLOOD LEVEL; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DOWN REGULATION; ENDOCYTOSIS; ENDOSOME; GENE MUTATION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; INTERNALIZATION; MEMBRANE PERMEABILITY; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN SECRETION;

AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; CALCIUM-BINDING PROTEINS; CELL MEMBRANE; CELLS, CULTURED; CHOLESTEROL; CLATHRIN; CLATHRIN-COATED VESICLES; DYNAMIN II; ENDOCYTOSIS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; PHOSPHOPROTEINS; RAB5 GTP-BINDING PROTEINS; SECRETORY PATHWAY;

EID: 77953260583     PISSN: 13881981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbalip.2010.05.010     Document Type: Article

References (34)

1. Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Small G.W., Roses A.D., Haines J.L., and Pericak-Vance M.A. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261 (1993) 921-923
2. Cutler R.G., Kelly J., Storie K., Pedersen W.A., Tammara A., Hatanpaa K., Troncoso J.C., and Mattson M.P. Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proc. Natl. Acad. Sci. USA 101 (2004) 2070-2075
3. Xiong H., Callaghan D., Jones A., Walker D.G., Lue L.F., Beach T.G., Sue L.I., Woulfe J., Xu H., Stanimirovic D.B., and Zhang W. Cholesterol retention in Alzheimer's brain is responsible for high beta- and gamma-secretase activities and A beta production. Neurobiol. Dis. 29 (2008) 422-437
4. Refolo L.M., Malester B., LaFrancois J., Bryant-Thomas T., Wang R., Tint G.S., Sambamurti K., Duff K., and Pappolla M.A. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol. Dis. 7 (2000) 321-331
5. Schrader-Fischer G., and Paganetti P.A. Effect of alkalizing agents on the processing of the beta-amyloid precursor protein. Brain Res. 716 (1996) 91-100
6. Thinakaran G., and Koo E.H. Amyloid precursor protein trafficking, processing, and function. J. Biol. Chem. 283 (2008) 29615-29619
7. Ehehalt R., Keller P., Haass C., Thiele C., and Simons K. Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J. Cell Biol. 160 (2003) 113-123
8. Grbovic O.M., Mathews P.M., Jiang Y., Schmidt S.D., Dinakar R., Summers-Terio N.B., Ceresa B.P., Nixon R.A., and Cataldo A.M. Rab5-stimulated up-regulation of the endocytic pathway increases intracellular beta-cleaved amyloid precursor protein carboxyl-terminal fragment levels and Abeta production. J. Biol. Chem. 278 (2003) 31261-31268
9. Carey R.M., Balcz B.A., Lopez-Coviella I., and Slack B.E. Inhibition of dynamin-dependent endocytosis increases shedding of the amyloid precursor protein ectodomain and reduces generation of amyloid beta protein. BMC Cell Biol. 6 (2005) 30
10. Schneider A., Rajendran L., Honsho M., Gralle M., Donnert G., Wouters F., Hell S.W., and Simons M. Flotillin-dependent clustering of the amyloid precursor protein regulates its endocytosis and amyloidogenic processing in neurons. J. Neurosci. 28 (2008) 2874-2882
11. Cirrito J.R., Kang J.E., Lee J., Stewart F.R., Verges D.K., Silverio L.M., Bu G., Mennerick S., and Holtzman D.M. Endocytosis is required for synaptic activity-dependent release of amyloid-beta in vivo. Neuron 58 (2008) 42-51
12. Simons M., Keller P., De Strooper B., Beyreuther K., Dotti C.G., and Simons K. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc. Natl. Acad. Sci. USA 95 (1998) 6460-6464
13. Kojro E., Gimpl G., Lammich S., Marz W., and Fahrenholz F. Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha -secretase ADAM 10. Proc. Natl. Acad. Sci. USA 98 (2001) 5815-5820
14. Guardia-Laguarta C., Coma M., Pera M., Clarimon J., Sereno L., Agullo J.M., Molina-Porcel L., Gallardo E., Deng A., Berezovska O., Hyman B.T., Blesa R., Gomez-Isla T., and Lleo A. Mild cholesterol depletion reduces amyloid-beta production by impairing APP trafficking to the cell surface. J. Neurochem. 110 (2009) 220-230
15. Leterrier C., Bonnard D., Carrel D., Rossier J., and Lenkei Z. Constitutive endocytic cycle of the CB1 cannabinoid receptor. J. Biol. Chem. 279 (2004) 36013-36021
16. Benmerah A., Poupon V., Cerf-Bensussan N., and Dautry-Varsat A. Mapping of Eps15 domains involved in its targeting to clathrin-coated pits. J. Biol. Chem. 275 (2000) 3288-3295
17. Motley A., Bright N.A., Seaman M.N., and Robinson M.S. Clathrin-mediated endocytosis in AP-2-depleted cells. J. Cell Biol. 162 (2003) 909-918
18. Citron M., Oltersdorf T., Haass C., McConlogue L., Hung A.Y., Seubert P., Vigo-Pelfrey C., Lieberburg I., and Selkoe D.J. Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. Nature 360 (1992) 672-674
19. Cossec J.C., Marquer C., Panchal M., Lazar A.N., Duyckaerts C., and Potier M.C. Cholesterol changes in Alzheimer's disease: Methods of analysis and impact on the formation of enlarged endosomes. Biochim. Biophys. Acta 1801 (2010) 839-845
20. Benmerah A., Gagnon J., Begue B., Megarbane B., Dautry-Varsat A., and Cerf-Bensussan N. The tyrosine kinase substrate eps15 is constitutively associated with the plasma membrane adaptor AP-2. J. Cell Biol. 131 (1995) 1831-1838
21. Stenmark H., Parton R.G., Steele-Mortimer O., Lutcke A., Gruenberg J., and Zerial M. Inhibition of rab5 GTPase activity stimulates membrane fusion in endocytosis. EMBO J. 13 (1994) 1287-1296
22. Koo E.H., and Squazzo S.L. Evidence that production and release of amyloid beta-protein involves the endocytic pathway. J. Biol. Chem. 269 (1994) 17386-17389
23. Haass C., Lemere C.A., Capell A., Citron M., Seubert P., Schenk D., Lannfelt L., and Selkoe D.J. The Swedish mutation causes early-onset Alzheimer's disease by beta-secretase cleavage within the secretory pathway. Nat. Med. 1 (1995) 1291-1296
24. Kang M.J., Chung Y.H., Hwang C.I., Murata M., Fujimoto T., Mook-Jung I.H., Cha C.I., and Park W.Y. Caveolin-1 upregulation in senescent neurons alters amyloid precursor protein processing. Exp. Mol. Med. 38 (2006) 126-133
25. Collawn J.F., Lai A., Domingo D., Fitch M., Hatton S., and Trowbridge I.S. YTRF is the conserved internalization signal of the transferrin receptor, and a second YTRF signal at position 31-34 enhances endocytosis. J. Biol. Chem. 268 (1993) 21686-21692
26. Lai A., Sisodia S.S., and Trowbridge I.S. Characterization of sorting signals in the beta-amyloid precursor protein cytoplasmic domain. J. Biol. Chem. 270 (1995) 3565-3573
27. Bouillot C., Prochiantz A., Rougon G., and Allinquant B. Axonal amyloid precursor protein expressed by neurons in vitro is present in a membrane fraction with caveolae-like properties. J. Biol. Chem. 271 (1996) 7640-7644
28. Beel A.J., Mobley C.K., Kim H.J., Tian F., Hadziselimovic A., Jap B., Prestegard J.H., and Sanders C.R. Structural studies of the transmembrane C-terminal domain of the amyloid precursor protein (APP): does APP function as a cholesterol sensor?. Biochemistry 47 (2008) 9428-9446
29. Beel A.J., Sakakura M., and Sanders C.R. Direct binding of cholesterol to the amyloid precursor protein: An important interaction in lipid-Alzheimer's disease relationships?. Biochim. Biophys. Acta 1801 (2010) 975-982
30. Gylys K.H., Fein J.A., Yang F., Miller C.A., and Cole G.M. Increased cholesterol in Abeta-positive nerve terminals from Alzheimer's disease cortex. Neurobiol. Aging 28 (2007) 8-17
31. Hudry E., Van Dam D., Kulik W., De Deyn P.P., Stet F.S., Ahouansou O., Benraiss A., Delacourte A., Bougneres P., Aubourg P., and Cartier N. Adeno-associated virus gene therapy with cholesterol 24-hydroxylase reduces the amyloid pathology before or after the onset of amyloid plaques in mouse models of Alzheimer's disease. Mol. Ther. 18 (2010) 44-53
32. Cataldo A.M., Peterhoff C.M., Troncoso J.C., Gomez-Isla T., Hyman B.T., and Nixon R.A. Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer's disease and Down syndrome: differential effects of APOE genotype and presenilin mutations. Am. J. Pathol. 157 (2000) 277-286
33. Cataldo A., Rebeck G.W., Ghetri B., Hulette C., Lippa C., Van Broeckhoven C., van Duijn C., Cras P., Bogdanovic N., Bird T., Peterhoff C., and Nixon R. Endocytic disturbances distinguish among subtypes of Alzheimer's disease and related disorders. Ann. Neurol. 50 (2001) 661-665
34. Jiang Y., Mullaney K.A., Peterhoff C.M., Che S., Schmidt S.D., Boyer-Boiteau A., Ginsberg S.D., Cataldo A.M., Mathews P.M., and Nixon R.A. Alzheimer's-related endosome dysfunction in Down syndrome is A{beta}-independent but requires APP and is reversed by BACE-1 inhibition. Proc. Natl. Acad. Sci. USA 107 (2009) 1630-1635